Tharun Alamuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tharun Alamuri has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Q. Duong
Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, USA
6 shared publications - Matthew Allan Thomas
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, USA
3 shared publications - Ryan C. Lee
Department of Radiology Montefiore Medical Center and Albert Einstein College of Medicine Bronx New York USA
3 shared publications - Christopher D. Malone
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
2 shared publications - J. Daniel Giardina
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63130
2 shared publications John Karageorgiou
Mallinckrodt Institute of Radiology, Washington University School of Medicine , St. Louis, MO 63110
2 shared publications
Latest Publications
- Top Cited Papers
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 319 (2) , e251923
Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma
Among patients with treatment-naive hepatocellular carcinoma, glass microsphere radiation segmentectomy before liver transplant achieved high rates of complete pathologic necrosis, which was positively associated with the number of optimized treatment parameter thresholds.
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 319 (2) , e251923
Top Cited PapersConsortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma
Among patients with treatment-naive hepatocellular carcinoma, glass microsphere radiation segmentectomy before liver transplant achieved high rates of complete pathologic necrosis, which was positively associated with the number of optimized treatment parameter thresholds.
- Open Access
- 5 February 2026
- Published by Oxford University Press (OUP) in Radiology Advances
- Vol. 3 (2)
When is patient-specific lung shunt fraction necessary in 90Y selective internal radiation therapy of liver cancer?
Lung shunt fraction (LSF) derived from macroaggregated albumin (MAA) based nuclear medicine imaging is a standard component of yttrium-90 selective internal radiation therapy (90Y-SIRT) treatment-planning. Elimination of MAA-based LSF determination has been suggested in selected cases. To propose and evaluate a pre-treatment identification method for patient-specific LSF that may influence treatment-planning in 90Y-SIRT and necessitate LSF determination using MAA-based imaging. MAA single photon emission computed tomography (SPECT)/CT based LSF (LSFSPECT) was analyzed retrospectively in glass 90Y-SIRT cases from September 2022 to June 2025 at a single center. A new metric (LSFbound) was defined as the minimum LSF value where the maximum achievable perfused volume (PV) dose becomes determined by a selected lung dose threshold (Lungsmax) instead of a designated whole-liver dose threshold (Livermax). LSFbound values computed using both clinical and simulated treatment planning parameters were quantitatively evaluated relative to LSFSPECT. A clinical workflow based on this new metric was evaluated. A total of 354 cases were analyzed from 297 patients (92 females and 205 males). Median (IQR) age at MAA-SPECT/CT was 69 (63–74). LSFbound depends only on liver mass, lung mass, Livermax, and Lungsmax, while PV size plays no role. Using observed LSFSPECT distributions, the median (max) probability for LSFSPECT to exceed LSFbound was ≤1% (≤4%) for HCC ≤ 8 cm and non-HCC cases without macrovascular invasion (87% of all cases). ROC analysis showed that the pre-treatment use of LSFbound could achieve 100% sensitivity and >60% specificities at Livermax values up to 180 Gy. Patient-specific, MAA-based LSF determination may be obviated in most 90Y-SIRT cases as LSF and Lungsmax play no role in limiting the achievable PV dose. Pre-treatment calculation of LSFbound provides individualized, quantitative guidance for identifying when MAA-based, patient-specific LSF assessment is warranted.
- 5 February 2026
- Published by Oxford University Press (OUP) in Radiology Advances
- Vol. 3 (2)
Open AccessWhen is patient-specific lung shunt fraction necessary in 90Y selective internal radiation therapy of liver cancer?
Lung shunt fraction (LSF) derived from macroaggregated albumin (MAA) based nuclear medicine imaging is a standard component of yttrium-90 selective internal radiation therapy (90Y-SIRT) treatment-planning. Elimination of MAA-based LSF determination has been suggested in selected cases. To propose and evaluate a pre-treatment identification method for patient-specific LSF that may influence treatment-planning in 90Y-SIRT and necessitate LSF determination using MAA-based imaging. MAA single photon emission computed tomography (SPECT)/CT based LSF (LSFSPECT) was analyzed retrospectively in glass 90Y-SIRT cases from September 2022 to June 2025 at a single center. A new metric (LSFbound) was defined as the minimum LSF value where the maximum achievable perfused volume (PV) dose becomes determined by a selected lung dose threshold (Lungsmax) instead of a designated whole-liver dose threshold (Livermax). LSFbound values computed using both clinical and simulated treatment planning parameters were quantitatively evaluated relative to LSFSPECT. A clinical workflow based on this new metric was evaluated. A total of 354 cases were analyzed from 297 patients (92 females and 205 males). Median (IQR) age at MAA-SPECT/CT was 69 (63–74). LSFbound depends only on liver mass, lung mass, Livermax, and Lungsmax, while PV size plays no role. Using observed LSFSPECT distributions, the median (max) probability for LSFSPECT to exceed LSFbound was ≤1% (≤4%) for HCC ≤ 8 cm and non-HCC cases without macrovascular invasion (87% of all cases). ROC analysis showed that the pre-treatment use of LSFbound could achieve 100% sensitivity and >60% specificities at Livermax values up to 180 Gy. Patient-specific, MAA-based LSF determination may be obviated in most 90Y-SIRT cases as LSF and Lungsmax play no role in limiting the achievable PV dose. Pre-treatment calculation of LSFbound provides individualized, quantitative guidance for identifying when MAA-based, patient-specific LSF assessment is warranted.
- Top Cited Papers
- 6 November 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (3) , 437-454
Use of Large Language Models on Radiology Reports: A Scoping Review
- 6 November 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 23 (3) , 437-454
Top Cited PapersUse of Large Language Models on Radiology Reports: A Scoping Review
- Open Access
- 17 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Ultra-selective radiation segmentectomy for early-stage hepatocellular carcinoma
- 17 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Open AccessUltra-selective radiation segmentectomy for early-stage hepatocellular carcinoma
- Open Access
- 10 September 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (1) , 107834
Modeling Clinical Relevance and Risk in Yttrium-90 Radioembolization of the Liver: Lung Shunt Fraction Variability According to Imaging Modality, Cancer Type, and Tumor Size
- 10 September 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (1) , 107834
Open AccessModeling Clinical Relevance and Risk in Yttrium-90 Radioembolization of the Liver: Lung Shunt Fraction Variability According to Imaging Modality, Cancer Type, and Tumor Size
- 9 September 2025
- Published by Elsevier in Brain Research
- Vol. 1866, 149940
Optimized dose of hydrogen-enriched water with minocycline combination therapy in experimental ischemic stroke
- 9 September 2025
- Published by Elsevier in Brain Research
- Vol. 1866, 149940
Optimized dose of hydrogen-enriched water with minocycline combination therapy in experimental ischemic stroke
- 16 December 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 103 (2) , 605-615
Long COVID-19 outcomes of patients with pre-existing dementia
Background: Although COVID-19 has been linked to worse acute outcomes in patients with some neurodegenerative disorders, its long-term impact on dementia remains unclear. Objective: To investigate the outcomes of COVID-19 survivors with dementia. Methods: This retrospective study evaluated 9806 patients with dementia in the Montefiore Health System (January 2016 to July 2023). Comparisons were made between dementia patients with and without a positive SARS-CoV-2 polymerase-chain-reaction test who had a follow-up at least two weeks post-infection. Outcomes included all-cause mortality, major adverse cardiovascular events (MACE), new-onset dysphagia, dyspnea, fatigue, new-onset sleep disturbances, altered mental status, first-time fall, headache, new-onset depression, and new-onset anxiety. Adjusted hazard ratios (aHR) were computed adjusting for age, sex, race, ethnicity, and pre-existing comorbidities. Results: Dementia patients with COVID-19 were younger, more likely to be male, and had a higher prevalence of major pre-existing comorbidities compared to those without COVID-19. Patients who survived acute COVID-19 were more likely to die than non-COVID controls after adjusting for covariates (aHR = 1.65 [1.43, 1.91]). COVID-19 was significantly associated with higher risk of MACE (aHR = 1.58 [1.41, 1.78]), new-onset dysphagia (aHR = 1.64 [1.42, 1.91]), dyspnea (aHR = 1.27 [1.12, 1.44]), fatigue (aHR = 1.42 [1.22, 1.65]), new-onset sleep disturbances (aHR = 1.36 [1.15, 1.60]), altered mental status (aHR = 1.36 [1.16, 1.59]), and first-time fall (aHR = 1.34 [1.09, 1.65]). Conclusions: COVID-19 increases the risk of mortality and other adverse health outcomes in dementia patients. These findings highlight the need for closer follow-up and management strategies for dementia patients post-COVID-19.
- 16 December 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 103 (2) , 605-615
Long COVID-19 outcomes of patients with pre-existing dementia
Background: Although COVID-19 has been linked to worse acute outcomes in patients with some neurodegenerative disorders, its long-term impact on dementia remains unclear. Objective: To investigate the outcomes of COVID-19 survivors with dementia. Methods: This retrospective study evaluated 9806 patients with dementia in the Montefiore Health System (January 2016 to July 2023). Comparisons were made between dementia patients with and without a positive SARS-CoV-2 polymerase-chain-reaction test who had a follow-up at least two weeks post-infection. Outcomes included all-cause mortality, major adverse cardiovascular events (MACE), new-onset dysphagia, dyspnea, fatigue, new-onset sleep disturbances, altered mental status, first-time fall, headache, new-onset depression, and new-onset anxiety. Adjusted hazard ratios (aHR) were computed adjusting for age, sex, race, ethnicity, and pre-existing comorbidities. Results: Dementia patients with COVID-19 were younger, more likely to be male, and had a higher prevalence of major pre-existing comorbidities compared to those without COVID-19. Patients who survived acute COVID-19 were more likely to die than non-COVID controls after adjusting for covariates (aHR = 1.65 [1.43, 1.91]). COVID-19 was significantly associated with higher risk of MACE (aHR = 1.58 [1.41, 1.78]), new-onset dysphagia (aHR = 1.64 [1.42, 1.91]), dyspnea (aHR = 1.27 [1.12, 1.44]), fatigue (aHR = 1.42 [1.22, 1.65]), new-onset sleep disturbances (aHR = 1.36 [1.15, 1.60]), altered mental status (aHR = 1.36 [1.16, 1.59]), and first-time fall (aHR = 1.34 [1.09, 1.65]). Conclusions: COVID-19 increases the risk of mortality and other adverse health outcomes in dementia patients. These findings highlight the need for closer follow-up and management strategies for dementia patients post-COVID-19.
- 26 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 636-643
Long‐term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID‐19: A 2.5‐year follow‐up study
Objectives: This study investigated whether patients with sickle cell disease (SCD) had elevated risk of worse long‐term clinical outcomes and healthcare utilization 2.5 years post‐SARS‐CoV‐2 infection.Methods: This study consisted of 178 patients with SCD who tested positive for COVID‐19 between February 1, 2020 and January 30, 2022 in a major academic health system in New York City. The control cohort consisted of two‐to‐one matches of 356 SCD patients without a COVID‐19 positive test. The last follow‐up was July 18, 2022. The primary outcome was mortality. Secondary outcomes were annualized emergency department visits due to pain, pain hospital admission, length of stay due to pain, acute chest syndrome, episodic transfusion, and episodic exchange transfusion.Results: There was no significant difference in mortality between SCD patients with and without COVID‐19 (p > .05). There were no significant differences in secondary outcomes between pre‐ and postpandemic (p > .05). There were also no significant differences in these outcomes between SCD patients with and without COVID‐19 (p > .05). SCD care utilization was not significantly associated with COVID‐19 hospitalization status (p > .05).Conclusions: SCD patients with SARS‐CoV‐2 infection incurred no additional risk of worse long‐term outcomes compared to matched controls of SCD patients not infected by SARS‐CoV‐2.
- 26 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 636-643
Long‐term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID‐19: A 2.5‐year follow‐up study
Objectives: This study investigated whether patients with sickle cell disease (SCD) had elevated risk of worse long‐term clinical outcomes and healthcare utilization 2.5 years post‐SARS‐CoV‐2 infection.Methods: This study consisted of 178 patients with SCD who tested positive for COVID‐19 between February 1, 2020 and January 30, 2022 in a major academic health system in New York City. The control cohort consisted of two‐to‐one matches of 356 SCD patients without a COVID‐19 positive test. The last follow‐up was July 18, 2022. The primary outcome was mortality. Secondary outcomes were annualized emergency department visits due to pain, pain hospital admission, length of stay due to pain, acute chest syndrome, episodic transfusion, and episodic exchange transfusion.Results: There was no significant difference in mortality between SCD patients with and without COVID‐19 (p > .05). There were no significant differences in secondary outcomes between pre‐ and postpandemic (p > .05). There were also no significant differences in these outcomes between SCD patients with and without COVID‐19 (p > .05). SCD care utilization was not significantly associated with COVID‐19 hospitalization status (p > .05).Conclusions: SCD patients with SARS‐CoV‐2 infection incurred no additional risk of worse long‐term outcomes compared to matched controls of SCD patients not infected by SARS‐CoV‐2.
- 30 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2482-2494
Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID ‐19 patients: Comparison with influenza and pre‐pandemic data
Aims: This study characterized incidence, patient profiles, risk factors and outcomes of in‐hospital diabetic ketoacidosis (DKA) in patients with COVID‐19 compared with influenza and pre‐pandemic data. Methods: This study consisted of 13 383 hospitalized patients with COVID‐19 (March 2020‐July 2022), 19 165 hospitalized patients with influenza (January 2018‐July 2022) and 35 000 randomly sampled hospitalized pre‐pandemic patients (January 2017‐December 2019) in Montefiore Health System, Bronx, NY, USA. Primary outcomes were incidence of in‐hospital DKA, in‐hospital mortality, and insulin use at 3 and 6 months post‐infection. Risk factors for developing DKA were identified. Results: The overall incidence of DKA in patients with COVID‐19 and influenza, and pre‐pandemic were 2.1%, 1.4% and 0.5%, respectively ( p < .05 pairwise). Patients with COVID‐19 with DKA had worse acute outcomes ( p < .05) and higher incidence of new insulin treatment 3 and 6 months post‐infection compared with patients with influenza with DKA ( p < .05). The incidence of DKA in patients with COVID‐19 was highest among patients with type 1 diabetes (12.8%), followed by patients with insulin‐dependent type 2 diabetes (T2D; 5.2%), non‐insulin dependent T2D (2.3%) and, lastly, patients without T2D (1.3%). Patients with COVID‐19 with DKA had worse disease severity and higher mortality [odds ratio = 6.178 (4.428‐8.590), p < .0001] compared with those without DKA. Type 1 diabetes, steroid therapy for COVID‐19, COVID‐19 status, black race and male gender were associated with increased risk of DKA. Conclusions: The incidence of DKA was higher in COVID‐19 cohort compared to the influenza and pre‐pandemic cohort. Patients with COVID‐19 with DKA had worse outcomes compared with those without. Many COVID‐19 survivors who developed DKA during hospitalization became insulin dependent. Identification of risk factors for DKA and new insulin‐dependency could enable careful monitoring and timely intervention.
- 30 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (9) , 2482-2494
Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID ‐19 patients: Comparison with influenza and pre‐pandemic data
Aims: This study characterized incidence, patient profiles, risk factors and outcomes of in‐hospital diabetic ketoacidosis (DKA) in patients with COVID‐19 compared with influenza and pre‐pandemic data. Methods: This study consisted of 13 383 hospitalized patients with COVID‐19 (March 2020‐July 2022), 19 165 hospitalized patients with influenza (January 2018‐July 2022) and 35 000 randomly sampled hospitalized pre‐pandemic patients (January 2017‐December 2019) in Montefiore Health System, Bronx, NY, USA. Primary outcomes were incidence of in‐hospital DKA, in‐hospital mortality, and insulin use at 3 and 6 months post‐infection. Risk factors for developing DKA were identified. Results: The overall incidence of DKA in patients with COVID‐19 and influenza, and pre‐pandemic were 2.1%, 1.4% and 0.5%, respectively ( p < .05 pairwise). Patients with COVID‐19 with DKA had worse acute outcomes ( p < .05) and higher incidence of new insulin treatment 3 and 6 months post‐infection compared with patients with influenza with DKA ( p < .05). The incidence of DKA in patients with COVID‐19 was highest among patients with type 1 diabetes (12.8%), followed by patients with insulin‐dependent type 2 diabetes (T2D; 5.2%), non‐insulin dependent T2D (2.3%) and, lastly, patients without T2D (1.3%). Patients with COVID‐19 with DKA had worse disease severity and higher mortality [odds ratio = 6.178 (4.428‐8.590), p < .0001] compared with those without DKA. Type 1 diabetes, steroid therapy for COVID‐19, COVID‐19 status, black race and male gender were associated with increased risk of DKA. Conclusions: The incidence of DKA was higher in COVID‐19 cohort compared to the influenza and pre‐pandemic cohort. Patients with COVID‐19 with DKA had worse outcomes compared with those without. Many COVID‐19 survivors who developed DKA during hospitalization became insulin dependent. Identification of risk factors for DKA and new insulin‐dependency could enable careful monitoring and timely intervention.
- 17 March 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (7) , 1785-1793
COVID ‐19 associated ketosis and diabetic ketoacidosis: A rapid review
SARS‐CoV‐2 infection could disrupt the endocrine system directly or indirectly, which could result in endocrine dysfunction and glycaemic dysregulation, triggering transient or persistent diabetes mellitus. The literature on the complex relationship between COVID‐19 and endocrine dysfunctions is still evolving and remains incompletely understood. Thus, we conducted a review on all literature to date involving COVID‐19 associated ketosis or diabetic ketoacidosis (DKA). In total, 27 publications were included and analysed quantitatively and qualitatively. Studies included patients with DKA with existing or new onset diabetes. While the number of case and cohort studies was limited, DKA in the setting of COVID‐19 seemed to increase risk of death, particularly in patients with new onset diabetes. Future studies with more specific variables and larger sample sizes are needed to draw better conclusions.
- 17 March 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (7) , 1785-1793
COVID ‐19 associated ketosis and diabetic ketoacidosis: A rapid review
SARS‐CoV‐2 infection could disrupt the endocrine system directly or indirectly, which could result in endocrine dysfunction and glycaemic dysregulation, triggering transient or persistent diabetes mellitus. The literature on the complex relationship between COVID‐19 and endocrine dysfunctions is still evolving and remains incompletely understood. Thus, we conducted a review on all literature to date involving COVID‐19 associated ketosis or diabetic ketoacidosis (DKA). In total, 27 publications were included and analysed quantitatively and qualitatively. Studies included patients with DKA with existing or new onset diabetes. While the number of case and cohort studies was limited, DKA in the setting of COVID‐19 seemed to increase risk of death, particularly in patients with new onset diabetes. Future studies with more specific variables and larger sample sizes are needed to draw better conclusions.